Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris (2011-00500-15)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Delenex Therapeutics AG
ClinicalTrials.gov Identifier:
NCT01595997
First received: May 9, 2012
Last updated: January 7, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2012
  Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)